1.Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients.
Haruko IWASE ; Toshio TAKADA ; Chiaki IITSUKA ; Hidetaka NOMURA ; Akiko ABE ; Tomoko TANIGUCHI ; Ken TAKIZAWA
Journal of Gynecologic Oncology 2015;26(4):303-310
OBJECTIVE: To investigate the clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery (IDS) in advanced epithelial ovarian cancer (EOC) patients. METHODS: We retrospectively reviewed the medical records of 124 advanced EOC patients and analyzed the details of neoadjuvant chemotherapy (NACT), IDS, postoperative treatment, and prognoses. RESULTS: Following IDS, 98 patients had no gross residual disease (NGRD), 15 had residual disease sized <1 cm (optimal), and 11 had residual disease sized > or =1 cm (suboptimal). Two-year overall survival (OS) and progression-free survival (PFS) rates were 88.8% and 39.8% in the NGRD group, 40.0% and 13.3% in the optimal group (p<0.001 vs. NGRD for both), and 36.3% and 0% in the suboptimal group, respectively. Five-year OS and 2-year PFS rates were 62% and 56.1% in the lymph node-negative (LN-) group and 26.2% and 24.5% in the lymph node-positive (LN+) group (p=0.0033 and p=0.0024 vs. LN-, respectively). Furthermore, survival in the LN+ group, despite surgical removal of positive nodes, was the same as that in the unknown LN status group, in which lymphadenectomy was not performed (p=0.616 and p=0.895, respectively). Multivariate analysis identified gross residual tumor during IDS (hazard ratio, 3.68; 95% confidence interval, 1.31 to 10.33 vs. NGRD) as the only independent predictor of poor OS. CONCLUSION: NGRD after IDS improved prognosis in advanced EOC patients treated with NACT-IDS. However, while systematic retroperitoneal lymphadenectomy during IDS may predict outcome, it does not confer therapeutic benefits.
Adult
;
Aged
;
Aged, 80 and over
;
Cytoreduction Surgical Procedures/*methods/mortality
;
Disease-Free Survival
;
Female
;
Humans
;
Lymph Node Excision/*methods/mortality
;
Lymphatic Metastasis
;
Middle Aged
;
Neoplasms, Glandular and Epithelial/mortality/*surgery
;
Ovarian Neoplasms/mortality/*surgery
;
Retroperitoneal Space
;
Retrospective Studies
;
Treatment Outcome
2.Strategies of diagnosis and treatment for peritoneal metastasis of gastric cancer.
Chinese Journal of Gastrointestinal Surgery 2017;20(5):500-503
Peritoneal metastasis of gastric cancer is the main cause of death in gastric cancer patients. Peritoneal metastasis of gastric cancer is difficult to diagnose in its early stage due to lack of obvious clinical signs and symptoms, and poor treatment outcomes and prognosis are often associated with late stage peritoneal metastasis. Therefore, it is crucial to utilize effective early diagnostic tools and to improve the long-term outcomes and the prognosis of patients with advanced gastric cancer. Recently, systemic chemotherapy and intraperitoneal chemotherapy are the first line therapy, and cytoreductive operation plus abdominal cavity thermochemotherapy may be the best method in the treatment of peritoneal metastasis. However, conversion therapy has been gradually incorporated into the treatment of peritoneal metastasis of gastric cancer because of the better efficacy and the higher survival.
Antineoplastic Agents
;
therapeutic use
;
Antineoplastic Protocols
;
Combined Modality Therapy
;
methods
;
Cytoreduction Surgical Procedures
;
Early Detection of Cancer
;
methods
;
Humans
;
Hyperthermia, Induced
;
Peritoneal Neoplasms
;
diagnosis
;
secondary
;
Prognosis
;
Stomach Neoplasms
;
mortality
;
pathology
;
Treatment Outcome